Marksans Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 24	Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20

Sales

853.27

655.20

658.29

599.55

433.42

Operating profit

139.94

91.90

113.72

113.71

71.49

Interest

0.99

3.61

3.80

5.35

7.29

Gross profit

201.02

148.77

152.17

139.52

64.37

EPS (Rs)

2.95

2.27

2.54

2.40

0.93

Other income

62.07

60.48

42.25

31.16

0.17

Stock adjustment

-7.25

-10.19

3.89

0.55

-5.63

Raw material

407.15

338.49

327.99

291.29

209.20

Power and fuel

-

-

-

-

-

Employee expenses

77.19

56.09

60.46

54.64

48.51

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

236.24

178.91

152.23

139.35

109.85

Provisions made

-

-

-

-

-

Depreciation

29.13

16.74

17.66

15.19

11.64

Taxation

38.13

29.17

30.52

25.95

14.82

Net profit / loss

133.76

102.87

103.99

98.38

37.90

Extra ordinary item

-

-

-

-

-

Prior year adjustments

-

-

-

-

-

Equity capital

45.32

45.32

40.93

40.93

40.93

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

16.40

14.03

17.27

18.97

16.49

GPM (%)

21.96

20.79

21.72

22.12

14.85

NPM (%)

14.61

14.37

14.84

15.60

8.74